| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium Infections | 40 | 2026 | 132 | 16.920 |
Why?
|
| Cross Infection | 16 | 2025 | 155 | 4.190 |
Why?
|
| Child | 71 | 2026 | 7745 | 3.070 |
Why?
|
| Anti-Bacterial Agents | 23 | 2026 | 880 | 2.770 |
Why?
|
| Hospitals, Pediatric | 10 | 2025 | 127 | 2.440 |
Why?
|
| Infection Control | 7 | 2025 | 134 | 2.420 |
Why?
|
| Enterocolitis, Pseudomembranous | 6 | 2019 | 52 | 2.210 |
Why?
|
| Bacterial Toxins | 7 | 2023 | 112 | 1.950 |
Why?
|
| Asymptomatic Infections | 3 | 2020 | 21 | 1.880 |
Why?
|
| Respiratory Tract Infections | 4 | 2025 | 112 | 1.780 |
Why?
|
| Infant | 30 | 2025 | 3358 | 1.770 |
Why?
|
| Polymerase Chain Reaction | 4 | 2018 | 894 | 1.710 |
Why?
|
| Child, Preschool | 31 | 2025 | 4038 | 1.680 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 341 | 1.450 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 337 | 1.450 |
Why?
|
| Communicable Diseases | 4 | 2023 | 74 | 1.420 |
Why?
|
| Fecal Microbiota Transplantation | 7 | 2026 | 89 | 1.330 |
Why?
|
| Whole Genome Sequencing | 5 | 2026 | 121 | 1.320 |
Why?
|
| Personnel, Hospital | 2 | 2021 | 31 | 1.300 |
Why?
|
| Betacoronavirus | 4 | 2020 | 286 | 1.280 |
Why?
|
| Humans | 101 | 2026 | 98362 | 1.260 |
Why?
|
| Feces | 10 | 2023 | 390 | 1.230 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2019 | 63 | 1.140 |
Why?
|
| Pandemics | 9 | 2023 | 913 | 1.110 |
Why?
|
| Communicable Diseases, Emerging | 3 | 2026 | 14 | 1.070 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 3 | 2021 | 33 | 0.980 |
Why?
|
| Nasopharynx | 3 | 2021 | 51 | 0.970 |
Why?
|
| Vancomycin | 4 | 2026 | 78 | 0.940 |
Why?
|
| Ribotyping | 3 | 2025 | 12 | 0.930 |
Why?
|
| Viral Load | 3 | 2021 | 162 | 0.920 |
Why?
|
| Health Personnel | 2 | 2025 | 257 | 0.870 |
Why?
|
| Bacterial Proteins | 6 | 2026 | 901 | 0.870 |
Why?
|
| Masks | 1 | 2025 | 31 | 0.860 |
Why?
|
| Virus Diseases | 1 | 2025 | 83 | 0.840 |
Why?
|
| Personal Protective Equipment | 3 | 2021 | 41 | 0.830 |
Why?
|
| Adolescent | 24 | 2025 | 10137 | 0.820 |
Why?
|
| Diarrhea | 5 | 2023 | 180 | 0.810 |
Why?
|
| Community-Acquired Infections | 3 | 2025 | 66 | 0.800 |
Why?
|
| Enterotoxins | 2 | 2022 | 22 | 0.770 |
Why?
|
| Chicago | 9 | 2026 | 1519 | 0.730 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2024 | 26 | 0.720 |
Why?
|
| Restriction Mapping | 2 | 2018 | 119 | 0.690 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 48 | 0.670 |
Why?
|
| Pharyngitis | 3 | 2026 | 18 | 0.670 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2019 | 41 | 0.670 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2026 | 151 | 0.660 |
Why?
|
| Incidence | 7 | 2025 | 1787 | 0.660 |
Why?
|
| Vaccination Refusal | 1 | 2021 | 15 | 0.660 |
Why?
|
| Schools | 1 | 2021 | 95 | 0.650 |
Why?
|
| Visitors to Patients | 1 | 2020 | 2 | 0.640 |
Why?
|
| Genome, Bacterial | 2 | 2018 | 144 | 0.620 |
Why?
|
| Organ Transplantation | 2 | 2025 | 306 | 0.620 |
Why?
|
| Gastroenterology | 2 | 2019 | 162 | 0.620 |
Why?
|
| Immunoenzyme Techniques | 2 | 2023 | 291 | 0.620 |
Why?
|
| Organizational Policy | 1 | 2020 | 56 | 0.610 |
Why?
|
| Fever | 1 | 2020 | 121 | 0.590 |
Why?
|
| Hospitals | 9 | 2023 | 335 | 0.590 |
Why?
|
| United States | 17 | 2025 | 8258 | 0.580 |
Why?
|
| Transplant Recipients | 2 | 2025 | 182 | 0.570 |
Why?
|
| Retrospective Studies | 19 | 2025 | 11039 | 0.550 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 56 | 0.520 |
Why?
|
| Infant, Newborn | 11 | 2025 | 2548 | 0.500 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 36 | 0.500 |
Why?
|
| Bacterial Infections | 2 | 2018 | 184 | 0.480 |
Why?
|
| Streptococcus pyogenes | 2 | 2026 | 38 | 0.480 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 100 | 0.480 |
Why?
|
| Antimicrobial Stewardship | 4 | 2020 | 27 | 0.480 |
Why?
|
| Genotype | 2 | 2018 | 1892 | 0.470 |
Why?
|
| Genomics | 2 | 2023 | 903 | 0.470 |
Why?
|
| Female | 28 | 2026 | 51756 | 0.460 |
Why?
|
| Bacteremia | 3 | 2025 | 110 | 0.460 |
Why?
|
| Mass Screening | 1 | 2021 | 751 | 0.460 |
Why?
|
| Coinfection | 4 | 2023 | 72 | 0.450 |
Why?
|
| Male | 27 | 2025 | 47257 | 0.450 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2024 | 11 | 0.440 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 72 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 74 | 0.440 |
Why?
|
| Surveys and Questionnaires | 3 | 2026 | 3032 | 0.440 |
Why?
|
| beta-Lactams | 2 | 2026 | 16 | 0.410 |
Why?
|
| Genetic Variation | 2 | 2025 | 1454 | 0.400 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 43 | 0.390 |
Why?
|
| Penicillin-Binding Proteins | 2 | 2026 | 3 | 0.380 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2026 | 53 | 0.370 |
Why?
|
| Risk Factors | 8 | 2025 | 6271 | 0.360 |
Why?
|
| Molecular Epidemiology | 3 | 2018 | 57 | 0.360 |
Why?
|
| Young Adult | 9 | 2021 | 7568 | 0.350 |
Why?
|
| Evolution, Molecular | 1 | 2018 | 904 | 0.350 |
Why?
|
| Sepsis | 3 | 2022 | 402 | 0.340 |
Why?
|
| Prospective Studies | 6 | 2023 | 4817 | 0.330 |
Why?
|
| Phylogeny | 4 | 2025 | 1340 | 0.330 |
Why?
|
| Adult | 13 | 2023 | 29587 | 0.310 |
Why?
|
| Vaccination | 5 | 2023 | 326 | 0.300 |
Why?
|
| Streptococcal Infections | 2 | 2026 | 58 | 0.290 |
Why?
|
| Diagnostic Errors | 2 | 2023 | 161 | 0.290 |
Why?
|
| Urinary Tract Infections | 2 | 2020 | 88 | 0.280 |
Why?
|
| Cohort Studies | 3 | 2022 | 3227 | 0.270 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 89 | 0.250 |
Why?
|
| Recurrence | 4 | 2023 | 1264 | 0.250 |
Why?
|
| Linezolid | 1 | 2026 | 5 | 0.250 |
Why?
|
| Measles | 1 | 2026 | 14 | 0.240 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2026 | 13 | 0.240 |
Why?
|
| Immunocompromised Host | 3 | 2025 | 139 | 0.240 |
Why?
|
| Dobutamine | 1 | 2006 | 38 | 0.240 |
Why?
|
| Atropine | 1 | 2006 | 53 | 0.240 |
Why?
|
| Echocardiography, Stress | 1 | 2006 | 15 | 0.240 |
Why?
|
| Disease Outbreaks | 1 | 2026 | 149 | 0.230 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2006 | 77 | 0.230 |
Why?
|
| Fungemia | 1 | 2025 | 15 | 0.230 |
Why?
|
| Cost of Illness | 1 | 2026 | 165 | 0.230 |
Why?
|
| Hospitalization | 5 | 2024 | 988 | 0.230 |
Why?
|
| Saccharomycetales | 1 | 2025 | 15 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1126 | 0.230 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 92 | 0.220 |
Why?
|
| Leadership | 3 | 2021 | 160 | 0.220 |
Why?
|
| Residential Facilities | 1 | 2024 | 4 | 0.220 |
Why?
|
| Electronic Health Records | 2 | 2019 | 450 | 0.210 |
Why?
|
| Health Care Costs | 1 | 2026 | 259 | 0.210 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 60 | 0.210 |
Why?
|
| Treatment Outcome | 7 | 2023 | 9770 | 0.200 |
Why?
|
| Superinfection | 1 | 2023 | 2 | 0.200 |
Why?
|
| Immunization | 2 | 2023 | 154 | 0.200 |
Why?
|
| Heart Rate | 1 | 2006 | 534 | 0.190 |
Why?
|
| Seasons | 2 | 2024 | 252 | 0.190 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 408 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 2056 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2019 | 2009 | 0.190 |
Why?
|
| Patient Acuity | 1 | 2022 | 38 | 0.190 |
Why?
|
| Heart Transplantation | 2 | 2025 | 874 | 0.180 |
Why?
|
| Hepatitis | 1 | 2022 | 32 | 0.180 |
Why?
|
| Vaccines | 1 | 2023 | 86 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2022 | 39 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2017 | 0.170 |
Why?
|
| Stem Cell Transplantation | 1 | 2023 | 195 | 0.170 |
Why?
|
| Faculty | 1 | 2021 | 40 | 0.170 |
Why?
|
| Drug Hypersensitivity | 1 | 2021 | 38 | 0.170 |
Why?
|
| Disinfection | 1 | 2021 | 15 | 0.170 |
Why?
|
| Shock, Septic | 1 | 2022 | 135 | 0.170 |
Why?
|
| Oropharynx | 1 | 2020 | 14 | 0.170 |
Why?
|
| Clostridium | 1 | 2020 | 25 | 0.160 |
Why?
|
| HeLa Cells | 1 | 2022 | 520 | 0.160 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 36 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2020 | 160 | 0.160 |
Why?
|
| Child, Hospitalized | 1 | 2020 | 38 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2020 | 42 | 0.160 |
Why?
|
| Hospital Administration | 1 | 2020 | 24 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 100 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2019 | 661 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 663 | 0.160 |
Why?
|
| Ultraviolet Rays | 1 | 2021 | 198 | 0.150 |
Why?
|
| RNA, Viral | 1 | 2021 | 288 | 0.150 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 120 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 79 | 0.150 |
Why?
|
| Patient Admission | 1 | 2020 | 123 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1116 | 0.150 |
Why?
|
| Prevalence | 2 | 2021 | 1393 | 0.150 |
Why?
|
| Neuroimaging | 1 | 2020 | 143 | 0.150 |
Why?
|
| Students | 1 | 2021 | 197 | 0.150 |
Why?
|
| Carrier State | 1 | 2019 | 40 | 0.150 |
Why?
|
| Child Health | 1 | 2019 | 15 | 0.140 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 192 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2019 | 214 | 0.140 |
Why?
|
| DNA Restriction Enzymes | 1 | 2018 | 76 | 0.140 |
Why?
|
| Aminoglycosides | 1 | 2018 | 31 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2019 | 65 | 0.140 |
Why?
|
| DNA Gyrase | 1 | 2018 | 2 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 889 | 0.140 |
Why?
|
| Palivizumab | 1 | 2018 | 1 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 942 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 369 | 0.130 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 479 | 0.130 |
Why?
|
| Health Facilities | 1 | 2018 | 43 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 22 | 0.130 |
Why?
|
| Catheter-Related Infections | 1 | 2017 | 26 | 0.130 |
Why?
|
| Central Venous Catheters | 1 | 2017 | 24 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 726 | 0.130 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2018 | 99 | 0.130 |
Why?
|
| Virulence Factors | 1 | 2018 | 117 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 992 | 0.130 |
Why?
|
| Patient Safety | 1 | 2019 | 235 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 45 | 0.130 |
Why?
|
| Virulence | 1 | 2018 | 280 | 0.130 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 236 | 0.120 |
Why?
|
| Inpatients | 1 | 2020 | 367 | 0.120 |
Why?
|
| Length of Stay | 1 | 2020 | 876 | 0.120 |
Why?
|
| Bacterial Typing Techniques | 1 | 2016 | 28 | 0.120 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 114 | 0.120 |
Why?
|
| Device Removal | 1 | 2017 | 170 | 0.120 |
Why?
|
| Bacterial Vaccines | 1 | 2016 | 44 | 0.120 |
Why?
|
| Bacteriological Techniques | 1 | 2016 | 39 | 0.120 |
Why?
|
| Age Factors | 1 | 2020 | 1974 | 0.110 |
Why?
|
| Neoplasms | 2 | 2022 | 3348 | 0.110 |
Why?
|
| Civil Defense | 1 | 2015 | 11 | 0.110 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 12 | 0.110 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 60 | 0.110 |
Why?
|
| Serotyping | 1 | 2015 | 28 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2015 | 48 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1945 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 287 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2016 | 180 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 292 | 0.100 |
Why?
|
| Public Health | 1 | 2015 | 161 | 0.100 |
Why?
|
| Pediatrics | 1 | 2019 | 421 | 0.100 |
Why?
|
| Animals | 3 | 2023 | 28981 | 0.100 |
Why?
|
| Logistic Models | 2 | 2015 | 1276 | 0.100 |
Why?
|
| Housing | 1 | 2013 | 51 | 0.100 |
Why?
|
| Rheumatic Fever | 1 | 2012 | 12 | 0.090 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2011 | 21 | 0.090 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2011 | 16 | 0.090 |
Why?
|
| Hypotension | 1 | 2011 | 77 | 0.080 |
Why?
|
| Heterozygote | 1 | 2011 | 392 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 419 | 0.070 |
Why?
|
| Aged | 3 | 2020 | 21844 | 0.070 |
Why?
|
| Clindamycin | 1 | 2026 | 15 | 0.060 |
Why?
|
| Conjugation, Genetic | 1 | 2026 | 19 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 837 | 0.060 |
Why?
|
| Quarantine | 1 | 2026 | 10 | 0.060 |
Why?
|
| Systole | 1 | 2006 | 81 | 0.060 |
Why?
|
| Ampicillin | 1 | 2026 | 17 | 0.060 |
Why?
|
| beta-Lactam Resistance | 1 | 2026 | 13 | 0.060 |
Why?
|
| Diastole | 1 | 2006 | 101 | 0.060 |
Why?
|
| Penicillins | 1 | 2026 | 25 | 0.060 |
Why?
|
| Middle Aged | 3 | 2020 | 29532 | 0.060 |
Why?
|
| Pakistan | 1 | 2025 | 18 | 0.060 |
Why?
|
| Urban Population | 1 | 2026 | 248 | 0.050 |
Why?
|
| Surge Capacity | 1 | 2024 | 2 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 1785 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2006 | 890 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 264 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2006 | 269 | 0.050 |
Why?
|
| Health Resources | 1 | 2024 | 80 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 55 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 55 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 78 | 0.050 |
Why?
|
| Metronidazole | 1 | 2022 | 26 | 0.050 |
Why?
|
| Blood Culture | 1 | 2022 | 13 | 0.050 |
Why?
|
| Infectious Disease Medicine | 1 | 2022 | 8 | 0.040 |
Why?
|
| Research Design | 1 | 2006 | 651 | 0.040 |
Why?
|
| Child Care | 1 | 2021 | 6 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2022 | 125 | 0.040 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 41 | 0.040 |
Why?
|
| Ethical Analysis | 1 | 2021 | 23 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 36 | 0.040 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2020 | 3 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 2020 | 19 | 0.040 |
Why?
|
| Argentina | 1 | 2020 | 15 | 0.040 |
Why?
|
| Peru | 1 | 2020 | 28 | 0.040 |
Why?
|
| France | 1 | 2020 | 53 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 93 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 2020 | 10 | 0.040 |
Why?
|
| India | 1 | 2020 | 148 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 212 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2024 | 428 | 0.040 |
Why?
|
| Parents | 1 | 2023 | 323 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 860 | 0.040 |
Why?
|
| Mothers | 1 | 2021 | 149 | 0.040 |
Why?
|
| Intestines | 1 | 2023 | 442 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2026 | 1419 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 112 | 0.040 |
Why?
|
| Research | 1 | 2020 | 257 | 0.040 |
Why?
|
| Mutation | 1 | 2011 | 4428 | 0.040 |
Why?
|
| Brain Diseases | 1 | 2020 | 178 | 0.040 |
Why?
|
| Critical Illness | 1 | 2022 | 361 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 622 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 83 | 0.040 |
Why?
|
| North America | 1 | 2019 | 210 | 0.030 |
Why?
|
| Phenotype | 1 | 2025 | 2667 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 74 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 602 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 357 | 0.030 |
Why?
|
| Policy Making | 1 | 2018 | 64 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2018 | 93 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2025 | 1234 | 0.030 |
Why?
|
| Cost Savings | 1 | 2018 | 68 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 676 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 102 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2070 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1077 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2018 | 369 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 251 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 687 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 381 | 0.030 |
Why?
|
| Software | 1 | 2018 | 697 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 3269 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 49 | 0.020 |
Why?
|
| Shock | 1 | 2011 | 48 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 335 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 104 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 5576 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2687 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 12735 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1570 | 0.020 |
Why?
|
| Echocardiography | 1 | 2006 | 784 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 7418 | 0.010 |
Why?
|